Literature DB >> 7815246

Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes.

B W Petschow1, R D Talbott.   

Abstract

Bovine milk immunoglobulin concentrates have been proposed for inducing passive immunity against various enteric pathogens. In vitro digestion studies were conducted to evaluate the effect of gastrointestinal secretions on the virus-neutralizing activity of a concentrate prepared from the colostrum of cows that were immunized with rotavirus. The proteolytic activity of human gastric and duodenal fluid specimens was used to design a two-stage in vitro digestion model with commercial enzymes for estimating the individual impact of pepsin, gastric acid, and select pancreatic enzymes on antirotavirus activity in bovine milk immunoglobulin concentrates. The rotavirus-neutralizing titer of concentrate was decreased by incubation with pepsin at pH 2, a pool of pancreatic enzymes at pH 7.5, or sequential digestion with pepsin (pH 2) and pancreatic enzymes (from initial titer of 55,210 to 2,030, 19,500, and 320, respectively). Reduction in rotavirus-neutralizing titer after gastric-phase digestion was primarily due to acidic conditions and not to proteolytic cleavage by pepsin. Although both trypsin and carboxypeptidase caused significant proteolysis of concentrate during duodenal-phase digestion, only trypsin caused a significant reduction in rotavirus-neutralizing titer. The extent of digestion was the same for concentrate suspended in water or skim milk. The results demonstrate that the biological activity of bovine milk antibodies is reduced by exposure to acid and trypsin in vitro and suggest that neutralization of both gastric acid and pancreatic trypsin may enhance the effectiveness and economic feasibility of passive oral immunoprophylaxis with bovine milk immunoglobulins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7815246     DOI: 10.1097/00005176-199408000-00014

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  8 in total

1.  Could the GI tract be a better portal for antibody therapy?

Authors:  S J Green; Jon Brendsel
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 2.  Oral delivery of antibodies. Future pharmacokinetic trends.

Authors:  R M Reilly; R Domingo; J Sandhu
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

3.  Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo.

Authors:  Edward Dolk; Marcel van der Vaart; David Lutje Hulsik; Gert Vriend; Hans de Haard; Silvia Spinelli; Christian Cambillau; Leon Frenken; Theo Verrips
Journal:  Appl Environ Microbiol       Date:  2005-01       Impact factor: 4.792

Review 4.  What makes a food protein an allergen?

Authors:  Gary A Bannon
Journal:  Curr Allergy Asthma Rep       Date:  2004-01       Impact factor: 4.919

5.  The effect of dietary intake of the acidic protein fraction of bovine colostrum on influenza A (H1N1) virus infection.

Authors:  Mei Ling Xu; Hyoung Jin Kim; Don Yong Chang; Hong-Jin Kim
Journal:  J Microbiol       Date:  2013-04-26       Impact factor: 3.422

6.  Safety of snake antivenom immunoglobulins: efficacy of viral inactivation in a complete downstream process.

Authors:  C P Caricati; L Oliveira-Nascimento; J T Yoshida; A T P Caricati; I Raw; M A Stephano
Journal:  Biotechnol Prog       Date:  2013-06-27

Review 7.  Passive immunisation, an old idea revisited: Basic principles and application to modern animal production systems.

Authors:  Chris J Hedegaard; Peter M H Heegaard
Journal:  Vet Immunol Immunopathol       Date:  2016-04-26       Impact factor: 2.046

Review 8.  Oral drug delivery for immunoengineering.

Authors:  Tien Le; Brian Aguilar; Joslyn L Mangal; Abhinav P Acharya
Journal:  Bioeng Transl Med       Date:  2021-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.